NKCx Histopathological outcome* within 12 months after cervix cytology in 2022
531 Skövde

  Benign LSIL HSIL AIS Cancer Other PAD missing Total
Cytologi Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel
Benign sample 537 4.4% 109 0.9% 26 0.2% . . 5 0.0% 5 0.0% 11566 94.4% 12248 100.0%
ASCUS 533 30.0% 393 22.1% 180 10.1% 4 0.2% 2 0.1% 4 0.2% 659 37.1% 1775 100.0%
LSIL 70 17.6% 147 37.0% 80 20.2% . . 2 0.5% 1 0.3% 97 24.4% 397 100.0%
Atypical glandular cells/AGC 14 38.9% 2 5.6% 4 11.1% 4 11.1% 5 13.9% . . 7 19.4% 36 100.0%
ASC-H 13 9.9% 25 19.1% 76 58.0% 5 3.8% 4 3.1% 1 0.8% 7 5.3% 131 100.0%
HSIL 6 9.0% 5 7.5% 46 68.7% . . 6 9.0% . . 4 6.0% 67 100.0%
Suspected Adenocarcinom 1 8.3% . . . . 2 16.7% 7 58.3% . . 2 16.7% 12 100.0%
Squamous cell cancer . . . . . . . . 1 100.0% . . . . 1 100.0%
Totalt 1174 8.0% 681 4.6% 412 2.8% 15 0.1% 32 0.2% 11 0.1% 12342 84.1% 14667 100.0%

NOTE: Histopathological outcome from T83x taken into account.
This list includes only one diagnosis (the highest ranking) per person, applies to both Cyt and Pad.

* Harmonization of PAD codes classification between analysis registry and process registry has been carried out. PAD Class 0 (non diagnostic, unreasonable diagnosis) is excluded, and next PAD counts instead.
The classes 2a, b, c and 3a (suspected premalignant, pre-malignant UNS, HPV, suspected malignant) are grouped into 'Other'.
Process Registry's Class 1 (benign), 2d (LSIL) and 3b (manifest cancer) have all been introduced without exception. Some codes that occur beyond the scope of the process registry has been added to the different categories.
 

Snomed codes in the category Cancer:
M69760, M80703, M81403, M83803, M84413, M85206